definiens: ) endpoint and progression - fr ee survival ( ) endpoint and ( B ) a prospectivel y defined high TROP-2 subgroup ( with a score of 3 or 4 ) trial fails to achieve its OS endpoint and its PFS endpo int ; ( b ) [ * * * ] Dollars ( $ [ * * * ] ) in the event that ei ther ( i ) the FDA revokes its approval for the mTNBC indication within [ * * * ] months of issuing its approval or ( ii ) ( A ) Company ’s ASCENT trial fails to achieve its OS endpoint and PFS endpoint and ( B ) a prospectively defined high TROP-2 subgroup ( with a score of 3 or 4 ) trial fails to achieve its OS endpoint a nd its PFS endpoint ; or ( c ) [ * * * ] Dollars ( $ [ * * * ] ) in the event that th e FDA revokes its approval for the mTNBC indication during the period commencing any time af ter [ * * * ] months after the FDA issued its approval and ending [ * * * ] months after the FDA issued its approval